Latest Clinical Data on Namenda for Alzheimer’s Patients Confirms Beneficial Effects

Latest Clinical Data on Namenda for Alzheimer’s Patients Confirms Beneficial Effects
Results from four recent studies confirmed the beneficial clinical effects of Namenda (memantine), an FDA-approved Alzheimer's therapy, to treat the disease's behavioral and functional symptoms in people with moderate to severe disease. The studies, sponsored by Allergan, are being presented in poster format at the 2017 annual meeting of the American Academy of Neurology (AAN), taking place through April 28 in Boston. Namenda blocks the activity of specific brain receptors that are believed to be associated with Alzheimer’s symptoms. Used to treat moderate to severe dementia, the drug is also suggested to have the potential to improve memory, awareness, and the ability to perform certain daily functions. Clinical data from a Phase 3 study, MEM-MD-50 (NCT00322153), which assessed Namenda's safety, tolerability, and effectiveness in treating Alzheimer's patients also taking cholinesterase inhibitors (ChEI) such as Aricept (donepezil), found the combined treatment did not improve patients' performance in daily living activities, but had a beneficial impact on their cognitive abilities. That study concluded in 2007. A new analysis of the data collected from the MEM-MD-50 study also shows that, while Namenda treatment did not stop functional decline in Alzheimer's patients, it helped to delay decline, a finding that confirms results from previous clinical trials. "The inevitable decline in function in moderate-to-severe [Alzheimer's] patients may be ameliorated with [Namenda] treatment compared with tr
Subscribe or to access all post and page content.


  1. Arne Brun says:

    Always grateful for your communications. Much of it eludes me now however since it is printed in weak colours, a common misstake by designers! I like many others with macular degeneration can not read such text, so please make it black against white. also please change my mailadress as below.

Leave a Comment

Your email address will not be published. Required fields are marked *